BofA raised the firm's price target on BioNTech to $130 from $128 and keeps a Buy rating on the shares after the company reported positive Phase 2 data for T-Pam in second-line and later HER2-expressing endometrial cancer. The firm is "encouraged by these positive results," which it thinks reinforce the potential for the first approval for BioNTech's growing oncology pipeline, the analyst tells investors.
